Product How it works Pricing Blog FAQ About Contact
Taysha Gene Therapies

Taysha Gene Therapies (NASDAQ: TSHA) revenue

Taysha Gene Therapies reported revenue of $9.8m for fiscal 2025, 17.3% more than in fiscal 2024 ($8.3m). Since fiscal 2022 its revenue has grown by 290.6%, an average growth of 57.5% a year.

Taysha Gene Therapies's best year of the last 4 was fiscal 2023. The biggest drop was in fiscal 2024, −46.1%.

Revenue, in millions of US dollars2.5202215.520238.320249.82025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$9.8m+17.3%−$110.5m−1,130.6%
2024$8.3m−46.1%−$91.5m−1,097.6%
2023$15.5m+517.5%−$72.4m−468.8%
2022$2.5m—−$162.4m−6,492.7%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Taysha Gene Therapies revenue compared with its sector

By revenue for its latest fiscal year, Taysha Gene Therapies ranks 369th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Taysha Gene Therapies, 17.3%.

RankCompanyRevenueRevenue growth
367thJanux Therapeutics$10.0m−5.6%
368thZenas BioPharma$10.0m100.0%
369thTaysha Gene Therapies$9.8m17.3%
370thPrecigen$9.7m146.7%
371stProthena Corporation Public$9.7m−92.8%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Taysha Gene Therapies

How much revenue did Taysha Gene Therapies make in fiscal 2025?
Taysha Gene Therapies reported revenue of $9.8m for fiscal 2025, compared with $8.3m in fiscal 2024.
How much has the revenue of Taysha Gene Therapies grown?
Between fiscal 2022 and fiscal 2025 it went from $2.5m to $9.8m: 290.6% more, an average growth of 57.5% a year.
What was the best year for revenue at Taysha Gene Therapies?
Of its last 4 fiscal years, fiscal 2023, with $15.5m.
Where does Taysha Gene Therapies rank in its sector by revenue?
It ranks 369th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Taysha Gene Therapies come from?
From the annual report (Form 10-K) that Taysha Gene Therapies files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Taysha Gene Therapies files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022. More on Taysha Gene Therapies: the Taysha Gene Therapies page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.